101 related articles for article (PubMed ID: 32932758)
1. Improved Progression-Free Long-Term Survival of a Nation-Wide Patient Population with Metastatic Melanoma.
Soerensen AV; Ellebaek E; Bastholt L; Schmidt H; Donia M; Svane IM
Cancers (Basel); 2020 Sep; 12(9):. PubMed ID: 32932758
[TBL] [Abstract][Full Text] [Related]
2. Real-World Impact of Immune Checkpoint Inhibitors in Metastatic Uveal Melanoma.
Bol KF; Ellebaek E; Hoejberg L; Bagger MM; Larsen MS; Klausen TW; Køhler UH; Schmidt H; Bastholt L; Kiilgaard JF; Donia M; Svane IM
Cancers (Basel); 2019 Oct; 11(10):. PubMed ID: 31623302
[TBL] [Abstract][Full Text] [Related]
3. Changes in the survival of adult patients with metastasized melanoma with the approval of immune checkpoint inhibitors: A retrospective study from the United States database.
Adhikari A; Cha E; Antala D; Sapkota S; Bhattarai U
Cancer Epidemiol; 2022 Dec; 81():102254. PubMed ID: 36162155
[TBL] [Abstract][Full Text] [Related]
4. Age-Based Disparities in Metastatic Melanoma Patients Treated in the Immune Checkpoint Inhibitors (ICI)
Safi M; Al-Azab M; Jin C; Trapani D; Baldi S; Adlat S; Wang A; Ahmad B; Al-Madani H; Shan X; Liu J
Front Immunol; 2021; 12():609728. PubMed ID: 34887846
[TBL] [Abstract][Full Text] [Related]
5. An immunotherapy survivor population: health-related quality of life and toxicity in patients with metastatic melanoma treated with immune checkpoint inhibitors.
O'Reilly A; Hughes P; Mann J; Lai Z; Teh JJ; Mclean E; Edmonds K; Lingard K; Chauhan D; Lynch J; Au L; Ludlow A; Pattison N; Wiseman T; Turajlic S; Gore M; Larkin J; Husson O
Support Care Cancer; 2020 Feb; 28(2):561-570. PubMed ID: 31089820
[TBL] [Abstract][Full Text] [Related]
6. Use of First-Line Immune Checkpoint Inhibitors and Association With Overall Survival Among Patients With Metastatic Melanoma in the Anti-PD-1 Era.
Lamba N; Ott PA; Iorgulescu JB
JAMA Netw Open; 2022 Aug; 5(8):e2225459. PubMed ID: 36006646
[TBL] [Abstract][Full Text] [Related]
7. Changes in Real-World Outcomes in Patients with Metastatic Renal Cell Carcinoma from the Molecular-Targeted Therapy Era to the Immune Checkpoint Inhibitor Era.
Ishihara H; Nemoto Y; Nakamura K; Tachibana H; Fukuda H; Yoshida K; Kobayashi H; Iizuka J; Shimmura H; Hashimoto Y; Tanabe K; Kondo T; Takagi T
Target Oncol; 2022 May; 17(3):307-319. PubMed ID: 35460475
[TBL] [Abstract][Full Text] [Related]
8. Anticoagulation with Factor Xa Inhibitors Is Associated with Improved Overall Response and Progression-Free Survival in Patients with Metastatic Malignant Melanoma Receiving Immune Checkpoint Inhibitors-A Retrospective, Real-World Cohort Study.
Haist M; Stege H; Pemler S; Heinz J; Fleischer MI; Graf C; Ruf W; Loquai C; Grabbe S
Cancers (Basel); 2021 Oct; 13(20):. PubMed ID: 34680252
[TBL] [Abstract][Full Text] [Related]
9. Role of immune checkpoint inhibitors in metastatic uveal melanoma: a single-center retrospective cohort study.
Vanaken L; Woei-A-Jin FJSH; Van Ginderdeuren R; Deroose CM; Laenen A; Missotten G; Thal DR; Bechter O; Schöffski P; Clement P
Acta Oncol; 2023 May; 62(5):480-487. PubMed ID: 37200223
[TBL] [Abstract][Full Text] [Related]
10. The survivorship experience for patients with metastatic melanoma on immune checkpoint and BRAF-MEK inhibitors.
Lai-Kwon J; Khoo C; Lo S; Milne D; Mohamed M; Raleigh J; Smith K; Lisy K; Sandhu S; Jefford M
J Cancer Surviv; 2019 Aug; 13(4):503-511. PubMed ID: 31165342
[TBL] [Abstract][Full Text] [Related]
11. Concurrent Immune Checkpoint Inhibitors and Stereotactic Radiosurgery for Brain Metastases in Non-Small Cell Lung Cancer, Melanoma, and Renal Cell Carcinoma.
Chen L; Douglass J; Kleinberg L; Ye X; Marciscano AE; Forde PM; Brahmer J; Lipson E; Sharfman W; Hammers H; Naidoo J; Bettegowda C; Lim M; Redmond KJ
Int J Radiat Oncol Biol Phys; 2018 Mar; 100(4):916-925. PubMed ID: 29485071
[TBL] [Abstract][Full Text] [Related]
12. Nationwide Survival Benefit after Implementation of First-Line Immunotherapy for Patients with Advanced NSCLC-Real World Efficacy.
Mouritzen MT; Carus A; Ladekarl M; Meldgaard P; Nielsen AWM; Livbjerg A; Larsen JW; Skuladottir H; Kristiansen C; Wedervang K; Schytte T; Hansen KH; Østby AC; Frank MS; Lauritsen J; Sørensen JB; Langer SW; Persson GF; Andersen JL; Frary JMC; Drivsholm LB; Vesteghem C; Christensen HS; Bjørnhart B; Pøhl M
Cancers (Basel); 2021 Sep; 13(19):. PubMed ID: 34638329
[TBL] [Abstract][Full Text] [Related]
13. Development of a Metastatic Uveal Melanoma Prognostic Score (MUMPS) for Use in Patients Receiving Immune Checkpoint Inhibitors.
Kelly D; Rose AAN; Muniz TP; Hogg D; Butler MO; Saibil SD; King I; Kamil ZS; Ghazarian D; Ross K; Iafolla M; Araujo DV; Waldron J; Laperriere N; Krema H; Spreafico A
Cancers (Basel); 2021 Jul; 13(14):. PubMed ID: 34298857
[TBL] [Abstract][Full Text] [Related]
14. Treatment Patterns and Real-World Outcomes for Locally Advanced or Metastatic Urothelial Cancer in the Era of Immunotherapy.
Hassler MR; Moedlagl V; Hindinger H; Krauter J; Klager S; Resch I; Huebner N; Yurdakul O; Ofner H; Korn SM; D'Andrea D; Gust K; Shariat SF
Eur Urol Focus; 2023 Dec; ():. PubMed ID: 38161107
[TBL] [Abstract][Full Text] [Related]
15. Intracranial Treatment in Melanoma Patients with Brain Metastasis Is Associated with Improved Survival in the Era of Immunotherapy and Anti-BRAF Therapy.
Dalmasso C; Pagès C; Chaltiel L; Sibaud V; Moyal E; Chira C; Sol JC; Latorzeff I; Meyer N; Modesto A
Cancers (Basel); 2021 Sep; 13(17):. PubMed ID: 34503304
[TBL] [Abstract][Full Text] [Related]
16. The real-world impact of modern treatments on the survival of patients with metastatic melanoma.
Donia M; Ellebaek E; Øllegaard TH; Duval L; Aaby JB; Hoejberg L; Køhler UH; Schmidt H; Bastholt L; Svane IM
Eur J Cancer; 2019 Feb; 108():25-32. PubMed ID: 30605822
[TBL] [Abstract][Full Text] [Related]
17. Trend and socioeconomic disparities in survival outcome of metastatic melanoma after approval of immune checkpoint inhibitors: a population-based study.
Li D; Duan H; Jiang P; Jiang X; He Z; Guo C; Mou Y
Am J Transl Res; 2020; 12(7):3767-3779. PubMed ID: 32774733
[TBL] [Abstract][Full Text] [Related]
18. Health care and socioeconomic costs for long-term survivors after implementation of checkpoint-inhibitors and targeted agents for metastatic melanoma.
Soerensen AV; Kjellberg J; Ibsen R; Bastholt L; Schmidt H; Svane IM
Eur J Cancer; 2023 Oct; 192():113288. PubMed ID: 37672816
[TBL] [Abstract][Full Text] [Related]
19. High-dose interleukin-2 and interferon as first-line immunotherapy for metastatic melanoma: long-term follow-up in a large unselected Danish patient cohort.
Bastholt L; Svane IM; Bjerregaard JK; Herrstedt J; Hróbjartsson A; Schmidt H
Eur J Cancer; 2019 Jul; 115():61-67. PubMed ID: 31108244
[TBL] [Abstract][Full Text] [Related]
20. Improved overall survival in dual compared to single immune checkpoint inhibitors in
Kartolo A; Yeung C; Kuksis M; Hopman W; Baetz T
Melanoma Manag; 2022 Apr; 9(1):MMT60. PubMed ID: 35497071
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
